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Abstract: Aspergillus spp. are a group of filamentous molds that were first described due to a perceived
similarity to an aspergillum, or liturgical device used to sprinkle holy water, when viewed under
a microscope. Although commonly inhaled due to their ubiquitous nature within the environment,
an invasive fungal infection (IFI) is a rare outcome that is often reserved for those patients who
are immunocompromised. Given the potential for significant morbidity and mortality within this
patient population from IFI due to Aspergillus spp., along with the rise in the use of therapies that
confer immunosuppression, there is an increasing need for appropriate initial clinical suspicion
leading to accurate diagnosis and effective treatment. Voriconazole remains the first line agent
for therapy; however, the use of polyenes, novel triazole agents, or voriconazole in combination
with an echinocandin may also be utilized. Consideration as to which particular agent and for
what duration should be made in the individual context for each patient based upon underlying
immunosuppression, comorbidities, and overall tolerance of therapy.
Keywords: aspergillosis; treatment; voriconazole; isavuconazole; combination therapy; posacaonzole;
echinocandins
1. Introduction
Invasive fungal infections (IFIs) are responsible for significant morbidity and mortality, particularly
in immunocompromised hosts. In this population, molds and specifically invasive aspergillosis,
have been found responsible for the increasing number of deaths from IFIs [1–4]. The number of patients
“at risk” for mold infections continues to increase with more intensive and prolonged chemotherapeutic
regimens, immunosuppressive practices, and novel immunotherapeutic agents.
Significant advances in our understanding of the epidemiology, clinical, and radiographic
manifestations of invasive aspergillosis have occurred, enabling further refinement of diagnostic testing
in different patient populations. The highest incidence of infection occurs in allogeneic hematopoietic
stem cell transplant recipients, although others including solid organ transplant recipients and those
with qualitative or quantitative granulocyte deficits, within the intensive care unit, or with structural
lung disease (e.g., preexisting cavities) are also at risk [2,5,6]. The majority of infections are caused
by Aspergillus fumigatus, A. flavus, A. niger, or A. terreus. Improvements in treatment have also
occurred with the availability of new antifungal agents and formulations, exhibiting improvements
in pharmacokinetic parameters and toxicity [7]. A recent study evaluating combination therapy
has also been completed, further expanding treatment options for patients with invasive pulmonary
aspergillosis (IPA) [8]. A number of novel agents are in various stages of clinical development (F2G and
novel glucan synthase inhibitors, among others) and may offer additional advantages over currently
available agents.
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This review will discuss the currently recommended agents for the treatment of invasive
aspergillosis, examine the results from key clinical trials, and outline the concerns that arise during the
care and follow-up of patients with this morbid infection.
2. Primary Treatment
The Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management
of aspergillosis have been recently updated (Table 1) [9]. Patients with a disease presentation consistent
with invasive aspergillosis should have antifungal treatment initiated while a formal diagnostic
workup is completed.
Table 1. Treatment recommendations for invasive aspergillosis.
Recommendation Drug Dosing Comments
Primary Voriconazole
6 mg/kg IV every 12 h times
two then 4 mg/kg IV every
12 h
Oral therapy at mg/kg
dosing or 200–300 mg every
12 h; TDM required
Alternatives Lipsosomal amphotericinB (L-AMB) 3–5 mg/kg/day IV
Isavuconazole
200 mg every 8 h IV or PO
times six then 200 mg daily
IV or PO
Need for TDM
remains undefined
Voriconazole plus
Anidulafungin
Vorizonazole as above plus
Anidulafungin 200 mg IV
daily times one then 100 mg
IV daily
Combination therapy
considered in severe
disease and with
hematologic malignancy
Amphotericin B Lipid
Complex (ABLC) 5 mg/kg/day IV
Secondary Caspofungin 70 mg IV daily times onethen 50 mg IV daily Monotherapy as salvage
Posaconazole
Oral suspension: 200 mg PO
every 8 h, Tablet: 300 mg PO
every 12 h times two then
300 mg PO daily,
Intravenous: 300 mg IV
every 12 h times two then
300 mg IV daily
Caution in use of tablet
formulation with acid
suppression; TDM required
Itraconazole 200 mg PO every 12 h TDM required
2.1. First-Line Therapy
Voriconazole
Voriconazole remains the preferred agent for the treatment of aspergillosis based on the pivotal
study of Herbrecht et al. [10]. This study was an unblinded randomized trial, designed to evaluate
the efficacy and safety of voriconazole (two doses of 6 mg/kg on Day 1, then 4 mg/kg twice daily for
at least seven days, followed by 200 mg orally twice daily or intravenous compared to amphotericin
B deoxycholate (1–1.5 mg/kg per day) as primary therapy for invasive aspergillosis. All patients in
this study exhibited proven or probable diseases. In this study, a complete or partial response was
considered a successful outcome.
One hundred forty-four patients received voriconazole, while 133 received amphotericin B
deoxycholate. The majority of patients in this study were hematopoietic stem-cell transplant recipients,
had acute leukemia, or had another hematologic disorder. Twelve weeks after the initiation of
antifungal therapy, successful responses were observed in 52.8% of voriconazole-treated patients
(complete responses, 20.8%; partial responses, 31.9%) and 31.6% of amphotericin-B-treated patients
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(complete responses, 16.5%; partial responses 15.0%). This absolute difference (52.7% − 31.5% = 21.2%)
had a confidence interval (CI) of 10.4–32.9.
Most importantly, the survival rate at 12 weeks was 70.8% in the voriconazole group and
57.9% in the amphotericin B group (HR, 0.59; 95% CI, 0.40–0.88). Patients receiving voriconazole
had fewer overall drug-related adverse events, although visual disturbance was common in the
voriconazole-treated group (44.8%).
Subsequent publications have found these visual disturbances to range from changes in light
perception and seeing “flashing lights” to visual hallucinations [11,12]. These effects are transient,
reversible with discontinuation of therapy, generally occur 30 min after the receipt of therapy, last for
~30 min, and occur in roughly 30% of patients [13].
2.2. Alternative First-Line Agents
Alternative therapeutic options include isavuconazole, voriconazole plus an echinocandin
(combination therapy), liposomal amphotericin B, and other lipid formulations of amphotericin B.
2.2.1. Isavuconazole
Isavuconazole is a new mold-active triazole agent with activity against the Mucorales,
Aspergillus spp., and yeasts [14,15]. A Phase 3 double-blind randomized study comparing isavuconazole
(200 mg IV (intravenous) three times daily for Days 1 and 2, followed by 200 mg once daily IV
(intravenous) or orally) to voriconazole (6 mg/kg IV twice daily on Day 1, followed by 4 mg/kg IV
twice daily on Day 2, then either 4 mg/kg IV twice daily or 200 mg oral twice daily from Day 3 onwards)
in the treatment of invasive aspergillosis has recently been completed [16]. The primary endpoint was
all-cause mortality at Day 42 in the intention-to-treat (ITT) population. The main secondary endpoint
was overall response to therapy. Similar to the aforementioned Herbrecht study [10], the majority of
patients in this study had underlying hematologic malignancy.
All-cause mortality through Day 42 for the ITT population was 18.6% in the isavuconazole-treated
group and 20.2% in the voriconazole-treated group (treatment difference: −1.6%; 95% CI: −7.8 to 5.7)
confirming the non-inferiority of isavuconazole. The overall response rates at the end of treatment
(EOT) were 35.0% in the isavuconazole group and 36.4% in the voriconazole group. Additionally,
isavuconazole had significantly fewer study drug-related adverse events than did voriconazole
(42.4% vs. 59.8%; p < 0.001). This 17% difference in drug-related adverse events (AEs) were
primarily the lower rates of hepatobiliary disturbance, photosensitivity, and visual changes in the
isavuconazole-treated group, although it is still recommended to monitor liver function tests for patients
receiving isavuconazole due to the possibility of hepatobiliary disturbance while on antifungal therapy.
2.2.2. Combination Therapy
Combination therapy has been supported by generally favorable in vitro and in vivo data [17–19].
These studies have examined polyenes and mold-active triazoles with echinocandins. Clinical data
has followed and a recently completed randomized trial compared voriconazole monotherapy to
combination therapy with voriconazole plus anidulafungin [8]. This trial enrolled 454 patients with
a hematologic malignancy in an attempt to assess the possible superiority of combination therapy
on 6-week survival. Mortality after 6 weeks was 19.3% for those receiving combination therapy,
and 27.5% for monotherapy recipients (p = 0.087, 95% CI: −19 to 1.5). Secondary mortality benefits
favored combination therapy. In a post-hoc analysis, patients diagnosed with probable aspergillosis
(the majority of patients in the study), had the largest effect on mortality (15.7% combination
vs. 27.3% monotherapy, p = 0.037, 95% CI, −22.7 to −0.4). This study was underpowered to assess
treatment superiority and it seems likely that combination therapy has a role in the treatment of
invasive aspergillosis. For this reason, the newly updated IDSA aspergillosis guidelines recommend
considering combination therapy in the setting of severe disease, particularly in patients with
hematologic malignancy.
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Other drug combinations are of interest and may be needed in selected clinical settings,
although they have not been conducted in the rigorous fashion of more recent Phase 3/4 trials.
In a small study, 30 patients with underlying hematologic malignancy and proven or probable invasive
aspergillosis were randomized to liposomal amphotericin B (L-AMB) (3 mg/kg/day) plus caspofungin
or high dose L-AMB alone (10 mg/kg/day). There were more complete or partial responses in the
combination group at the end of therapy (67% vs. 27%, p < 0.03) and a trend towards a greater response
at 12 weeks (80% vs. 67%). Survival at 12 weeks was 100% vs. 80%, respectively, but all deaths were
due to progressive hematologic disease, and in only one was invasive aspergillosis deemed to be
contributory. Interestingly, elevated creatinine was more frequently seen in the monotherapy group
(23% vs. 7%) [20]. Given the availability of alternative agents with lower toxicity profiles, it seems
unlikely that a larger study will be conducted.
Other drug combinations appear promising [21], but clinical trials have yet to be undertaken
to subject these to the same level of scrutiny. Additional questions of optimal drug combinations,
optimal drug dosing, pharmacokinetic interactions, potential toxic interactions or in vivo antagonism,
and cost-benefit ratios of primary combination antifungal therapy require further investigation.
2.2.3. Liposomal Amphotericin B
Another alternative agent as primary therapy is liposomal amphotericin B (L-AMB). L-AMB has
been evaluated in multiple small randomized trials and demonstrated efficacy although the most
compelling data demonstrating effectiveness was observed in the AmBiLoad Trial [22]. This study
followed animal data that suggested higher doses of liposomal amphotericin B could improve
outcomes [23].
The AmBiLoad trial was a double-blind study evaluating the response to L-AMB at either 3 or
10 mg/kg per day for 14 days followed by 3 mg/kg per day. The primary end point was a favorable
(complete or partial) response at the end of the study treatment. Although this study included all
patients with invasive mold infections, aspergillosis accounted for 97% of the total cases. A favorable
response was seen in 50% vs. 46% of patients in the 3- and 10-mg/kg per day groups, respectively
(treatment difference 4%; 95% CI, −10% to 18%; p > 0.05), and survival rates at 12 weeks were 72% and
59%, respectively. Higher rates of nephrotoxicity and hypokalemia were seen in the 10 mg/kg per day
group. Therefore, there appears to be no benefit, and significant harm, with the higher L-AMB dosing
strategy in the treatment of invasive aspergillosis.
2.2.4. Other Lipid Amphotericin B Formulations
Other lipid formulations of amphotericin B have been evaluated in smaller studies. A single
randomized trial evaluated amphotericin B colloidal dispersion formulation (ABCD) at 6 mg/kg/day
to amphotericin B deoxycholate (AmB) at 1 or 1.5 mg/kg/day for the treatment of patients with
invasive aspergillosis. A total of 174 patients were enrolled and response rates were not found different
between groups—52% in the ABCD group and 51% in the AmB group (p = 0.96)—and morality
differences were also not observed (36% vs. 45%; p = 0.4) [24]. Infusion related reactions were more
common in the ABCD group, although renal toxicity was less common. ABCD is not recommended
unless other therapeutic options are unavailable.
Another lipid AmB alternative is ABLC (5 mg/kg/day), which has not been studied in
randomized trials for IA, but has been reported to be effective in observational studies, particularly
in the setting of salvage infection [25–28]. ABLC is generally well-tolerated compared with AmB,
but, similar to ABCD, is not generally used given the availability of other agents.
2.2.5. Echinocandins
Primary therapy with an echinocandin as monotherapy should not be used. This class had had
limited evaluation in the treatment of aspergillosis, although caspofungin has exhibited efficacy in
small non-comparative studies of drug administered for both primary and “salvage” therapy [29–35].
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The updated IDSA guidelines do not support the use of echinocandins as monotherapy based on a lack
of robustly powered comparative trials. In the rare situation where both triazoles and polyenes are
contraindicated, an echinocandin (micafungin or caspofungin) can be used. Anidulafungin has not
been sufficiently evaluated for inclusion.
2.2.6. Posaconazole
Posaconazole is available as an oral suspension, delayed-release tablet and intravenous formulation,
but has been studied primarily as primary prophylaxis against invasive aspergillosis [36,37].
Primary therapy of IA with posaconazole is not recommended due to the lack of proven efficacy
as primary therapy. An industry sponsored study designed to evaluate the safety and efficacy of
posaconazole versus voriconazole for the treatment of invasive aspergillosis is currently ongoing
(ClinialTrials.gov NCT01782131). At this time, posaconazole remains a useful agent in the salvage
setting [38].
2.2.7. Itraconazole
Itraconazole is available as an oral solution or capsule, while intravenous intraconazole has
limited availability. Itraconazole is used primarily as a corticosteroid sparing agent in non-invasive
forms of aspergillosis or as an alternative agent to posaconazole in the prophylaxis against IA [9].
In a prior study evaluating itraconazole in the treatment of invasive aspergillosis, only 39% had
a complete or partial response [39]. Given the availability of other agents, the poor bioavailability of
itraconazole and multiple drug–drug interactions, itraconazole should be used in the treatment of
invasive aspergillosis only if all other options have been exhausted.
3. Duration of Therapy
The duration of therapy for invasive aspergillosis has not been well-defined; however, it is
generally recommended that treatment be continued for a minimum of 6–12 weeks [9]. The duration
and degree of immunosuppression, the site and burden of disease, and demonstration of symptomatic
improvement should all be considered prior to the cessation of therapy. The decision to stop
therapy should follow serial clinical examination of all signs and symptoms, and follow-up
radiographic imaging.
The natural history of invasive aspergillosis in the immunosuppressed patient can complicate
follow-up, and it is important to recall the volume of pulmonary infiltrates may increase for the first
7–10 days of therapy, especially in the context of granulocyte recovery [40]. The use of serial serum
GM (galactomannan) assays for therapeutic monitoring is promising but remains investigational.
However, increases in Aspergillus antigen levels signify a poor prognosis.
Patients exhibiting a response to therapy should receive secondary prophylaxis if subsequent
immunosuppression is anticipated. Secondary prophylaxis is maintained for the duration of
immunosuppression in an attempt to prevent disease recurrence.
4. Adjunctive Therapy
4.1. Medical Therapy
Attempts to ameliorate underlying immunologic derangements that predispose to invasive fungal
infections are of paramount importance. Withholding chemotherapy until clinical improvement,
reducing or stopping immunosuppressive medications, and the correction of underlying comorbidities
that predispose to invasive disease (e.g., diabetic ketoacidosis) are all essential. In the neutropenic
patient, the use of colony stimulating factors (granulocyte-colony stimulating factor (G-CSF) or
granulocyte macrophage-colony stimulating factor (GM-CSF)) are recommended in attempts to
minimize the duration of neutropenia.
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Granulocyte transfusions are frequently used as adjunctive therapy; however, there are potential
harms to this approach with acute lung injury observed in past studies [41]. A recently completed
study evaluated neutropenic patients who received standard antimicrobial therapy vs. standard
antimicrobial therapy plus daily granulocyte transfusions and dexamethasone [42]. The overall success
rate at Day 42 was no different between groups, with 42% vs. 43% (p > 0.99) of patients exhibiting
a successful response to treatment.
4.2. Surgery
Surgical intervention is indicated in patients with invasive aspergillosis contiguous with critical
structures such as the great vessels (aorta, vena cava) or critical organs. Recalcitrant or massive
hemoptysis from a single focus, or lesions within bones, also frequently requires surgical intervention.
From retrospective studies, it appears surgical intervention is also important in the control of
invasive fungal sinusitis [43], endocarditis [44,45], or focal central nervous system disease [46].
Localized cutaneous disease also frequently benefits from surgical debridement.
5. Conclusions and Future Directions
Invasive aspergillosis is an extremely morbid infection of increasing significance given
the wide-spread use of many immunosuppressive agents for a variety of clinical purposes.
While voriconazole monotherapy remains the primary therapeutic option, alternatives such as
liposomal amphotericin B, isavuconazole, and voriconazole with an echinocandin as combination
therapy are reasonable primary alternatives in the appropriate clinical setting. Echinocandins
alone as monotherapy are generally avoided except in salvage therapy or when there are
contraindications of primary alternatives. Duration of therapy, which should be individualized based
upon degree of immunosuppression and site of infection, however, is often for at least 6–12 weeks.
Surgical intervention should be adjunctively considered for recalcitrant disease or invasion of vascular
structures, critical organs, bone, or local cutaneous disease. Important directions for future research
should evaluate an appropriate duration of therapy in addition to examining the efficacy of newer
pharmaceutical agents. Additional optimization of current drugs in combination for the purpose
of maximizing therapeutic effect while minimizing toxicities would be another important avenue
of study.
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